UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/602,077	06/23/2003	Stephen Suffin	CNSR-09275	1225
23535 MEDLEN & CA	7590 09/04/200 ARROLL, LLP	EXAMINER		
101 HOWARD STREET SUITE 350 SAN FRANCISCO, CA 94105			JONES, DAMERON LEVEST	
			ART UNIT	PAPER NUMBER
			1618	
			MAIL DATE	DELIVERY MODE
			09/04/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/602,077	SUFFIN, STEPHEN
Office Action Summary	Examiner	Art Unit
	D L. Jones	1618
The MAILING DATE of this communication appeariod for Reply	pears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailine earned patent term adjustment. See 37 CFR 1.704(b).	NATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		
Responsive to communication(s) filed on 25 A This action is FINAL . 2b) ☑ This Since this application is in condition for allowated closed in accordance with the practice under A	s action is non-final. ince except for formal matters, pro	
Disposition of Claims		
4) ☐ Claim(s) 40-42,50-56 and 61-64 is/are pendin 4a) Of the above claim(s) 61-64 is/are withdray 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 40-42 and 50-56 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/o	wn from consideration.	
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E	cepted or b) objected to by the I drawing(s) be held in abeyance. See tion is required if the drawing(s) is objection.	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureat * See the attached detailed Office action for a list	ts have been received. ts have been received in Applicati prity documents have been receive au (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal F 6) Other:	ate

Art Unit: 1618

ACKNOWLEDGMENTS

1. The Examiner acknowledges receipt of the amendment filed 8/25/09 wherein claims 1-39, 43-49, and 57-60 were canceled and claims 40 and 54 were amended. In addition, the Examiner acknowledges receipt of the request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 8/25/09 has been entered.

Note: Claims 40-42, 50-56, and 61-64 are pending.

RESPONSE TO APPLICANT'S AMENDMENT/ARGUMENTS

2. The Applicant's arguments and/or amendment filed 8/25/09 to the rejection of claims 40-42 and 50-56 made by the Examiner under 35 USC 103 and/or 112 have been fully considered and deemed persuasive-in part for the reasons set forth below.

112 First Paragraph Rejection

The 112, first paragraph, rejection is WITHDRAWN because Applicant has amended the claim to overcome the rejection.

112 Second Paragraph Rejections

The 112, second paragraph, rejection is WITHDRAWN because Applicant has amended the claim to overcome the rejection.

Art Unit: 1618

103 Rejection

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

The rejection of claims 40-42 and 50-56 under 35 USC 103(a) as being unpatentable over John (US Patent No. 6,067,467) is MAINTAINED for reasons of record in the office action mailed 4/28/09 and those set forth below.

In summary, Applicant asserts that the cited prior art, John, does not teach the step of obtaining a second electroencephalogram from an awake patient for comparison to a first electroencephalogram. In addition, Applicant asserts that any interpretation of John that the second electroencephalogram might be from an awaken patient would result in an 'inoperable invention'.

Applicant's arguments are non-persuasive for the following reasons. The term 'awake' as defined by Merriam-Webster Online Dictionary ("awake." Merriam-Webster Online Dictionary. 2009. Merriam-Webster Online. 2 September 2009, http://www.merriam-webster.com/dictionary/awake), means 'to rouse from sleep', 'to become aware or cognizant', 'to rouse from a quiescent or inactive state', 'to make active' or 'to stir'. In John, a patient monitoring system is disclosed wherein an electrocephalograph (EEG) is used for patients during and after a medical procedure (see entire document, especially, abstract). Specially, the process involves (a) preoperative preparation of the patient wherein initial EEG measurements are taken while the patient is awake, preferably, before the anesthesia is administered (column 4, lines 22-44). (b) In the intra-operative stage, EEG data is obtained for a patient during the

Art Unit: 1618

surgical procedure (column 8, lines 17-38). (c) Next, the patient may be monitored in the recovery room/ICU using the EEG system disclosed in John. The recovery room/ICU monitoring enables the doctor to obtain a new self norm for the patient at each stage of recovery (i.e., as muscle paralysis is lessened and the patient becomes conscious). If the patient regresses, statistical data will illustrate such regression. The trajectories may be plotted against the self *norms* (Note that the plural of the term 'norm' indicates that multiple EEGs have been taken) of the patient being monitored for the most sensitive detection of clinically significant fluctuation within each patient, against populations norms to assess deviation from healthy persons; or against group average values constructed against some reference group of patients (column 14, lines 25-63 and columns 14-15, bridging paragraph). Thus, based on the disclosure of John, it would be obvious to a skilled practitioner in the art to take additional EEGs of an awaken patient because the reference discloses that multiple EEGs are taken of the patient. The EEGs are obtained prior to the operative procedure, during the operative procedure, and after the operative procedure (recovery room/ICU) when the subject is 'awaken'. Hence, a second EEG when a patient is 'awake' is within the scope of John. While John takes various EEGs and analyze the data such that multiple EEGs are obtained prior to the patient being 'awaken' from the anesthesia, any EEGs taken during recovery/ICU after the anesthesia wears off results in the patient being awaken from an inactive state. As a result, the method steps of the instant invention 'comprise' obtaining two EEGs, one of which is referred to as 'the second EEG taken when the patient is awaken' is within the scope of John. Furthermore, it is noted that the term 'comprise' as

Art Unit: 1618

in the instant invention, allows for additional steps (i.e., obtaining various EEGs before a patient is awaken) to be present. Thus, the rejection is deemed proper.

WITHDRAWN CLAIMS

3. Claims 61-64 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention/species.

Notes: It is duly noted that Applicant asserts that claims 61-64 merely represent an amendment of claim 1. In addition, it is asserted that the fundamental scope of the invention embodied by claims 61-64 have not been substantially changed such that now the Examiner faces an undue examination burden.

Applicant's arguments are non-persuasive for the following reasons. First, claim 1 has never been examined in the instant application. The claim was withdrawn from consideration from the very beginning of prosecution. Specifically, in Applicant's preliminary amendment filed 6/23/03, Applicant requested that claims 1-39 and 46-49 be withdrawn from consideration. In the office action mailed 5/25/05, page 2, first paragraph, the Examiner acknowledged the preliminary amendment and Applicant's request that the claims be withdrawn. Secondly, if Applicant is referring to claim 40 instead of claim 1, the search of claims 61-64 is of a different scope. In particular, independent claim 61 does not require a second EEG and the steps of step d (claim 61) are not required for claim 40, neither are they obvious modifications of claim 40. Thus, claims 61-64 will remain withdrawn by original presentation.

Art Unit: 1618

NEW GROUNDS OF REJECTION

Double Patenting Rejection

4. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Application/Control Number: 10/602,077

Art Unit: 1618

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Page 7

5. Claims 40-42 and 50-56 are rejected on the ground of nonstatutory obviousnesstype double patenting as being unpatentable over claims 1-8, 10-18, and 22-29 of U.S. Patent No. 6,622,036. Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims involve determining the medication efficacy. The claims differ in that those of the patented invention not only determine the medication efficacy, but use such date for treating physiologic brain imbalances. Thus, it would have been obvious to a skilled artisan at the time the invention was made that both inventions disclose overlapping subject matter because (1) both inventions disclose taking multiple EEGs and analyzing the data after administering a drug/medication (see patented claim 28); (2) generating univariate Z scores (see patented claims 14-18), and (3) determining the differential change between the data obtained. Furthermore, the skilled artisan would recognize that if one determines the efficacy by administering medicines and analyzing the data, it is inherent that one is being treated for a brain abnormality as in the patented invention because the skilled artisan would recognize that in the medical field the purpose of an EEG is to generate a graphic record of the electric activity of the brain to determine the absence/presence of abnormalities.

Art Unit: 1618

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to D L. Jones whose telephone number is (571)272-0617.

The examiner can normally be reached on Mon.-Fri., 6:45 a.m. - 3:15 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/D L. Jones/ Primary Examiner Art Unit 1618